ACR Convergence 2026: What Were the Key Takeaways for Rheumatology?

ACR Convergence 2026 brought attention to important questions in rheumatology research, including the future of osteoarthritis treatment, advances in personalised medicine in rheumatology and emerging approaches to rheumatoid arthritis treatment. From earlier diagnosis to targeted therapies, these developments highlight the challenges of improving long-term outcomes for patients living with rheumatic diseases.

Following the congress, we invited a healthcare professional who attended ACR Convergence 2026 to share their perspectives on the research areas requiring greater attention, emerging treatment approaches and developments that could influence clinical practice.

Their responses highlighted several important themes, including the need for disease-modifying treatments in osteoarthritis, more accurate treatment selection and the importance of identifying patients who may benefit from earlier intervention. The discussion also raised questions about the safety of existing therapies and the potential of newer approaches to address patients who do not respond adequately to current treatments.

Explore ACR Convergence 2026 insights into rheumatology research, osteoarthritis treatment, personalised medicine in rheumatology and rheumatoid arthritis treatment.

Osteoarthritis Treatment: Why Disease-Modifying Therapies Remain a Priority

Despite advances in rheumatology research, osteoarthritis remains a significant area of unmet clinical need. Current management largely focuses on symptom relief, maintaining mobility and supporting joint function. However, treatments capable of reliably preventing or reversing cartilage deterioration remain limited.

The participant identified osteoarthritis as one of the conditions requiring greater attention from researchers and clinicians.

“Osteoarthritis remains one of the major unmet needs in rheumatology. There is a pressing need to develop disease-modifying treatments capable of slowing or preventing cartilage degradation, promoting cartilage regeneration, or even restoring damaged cartilage.”

ACR Convergence 2026 participant

This perspective highlights an important distinction between managing symptoms and changing the underlying course of a disease.

In osteoarthritis, progressive cartilage damage can affect joint function and contribute to persistent pain, stiffness and reduced mobility. Developing treatments that protect or restore cartilage could therefore represent a significant advance.

Several experimental approaches are being investigated, including regenerative injections, stem cell-based therapies and strategies designed to stimulate chondrocyte formation. Chondrocytes are the specialised cells responsible for maintaining cartilage tissue.

These approaches aim to support cartilage repair or regeneration rather than simply manage discomfort. However, their long-term effectiveness, safety and suitability for routine clinical practice require further investigation.

Future osteoarthritis treatment research will need to establish whether regenerative strategies can produce meaningful structural improvements and whether those improvements translate into better pain control, mobility and quality of life.

Personalised Medicine in Rheumatology: How Close Are We?

The movement towards more individualised treatment was another important theme in the participant’s reflections. Personalised medicine in rheumatology aims to match treatment decisions more closely with a patient’s disease characteristics, biological markers and individual needs.

The participant noted that clinicians increasingly consider autoantibody profiles, disease phenotypes, extra-articular manifestations and the inflammatory pathways involved when selecting treatments.

“We are not yet at the point where treatment can be fully tailored to each individual patient with optimal predictive accuracy. Further advances in biomarkers and our understanding of disease mechanisms will be essential to achieve this goal.”

ACR Convergence 2026 participant

This reflects a challenge across several inflammatory rheumatic diseases. Although clinicians have access to a growing range of targeted therapies, predicting which treatment will work best for an individual patient remains difficult.

Two patients with the same diagnosis may experience different disease patterns, responses to treatment and adverse effects. More reliable biomarkers could help identify these differences earlier and support better treatment selection.

For example, understanding which inflammatory pathways are most active in a particular patient could eventually help clinicians choose therapies with greater confidence. However, personalised treatment also requires evidence that biomarker-guided decisions improve outcomes compared with existing approaches.

The next stage of rheumatology research will therefore involve not only identifying new biological markers, but also demonstrating how they can be used to make meaningful clinical decisions.

Explore ACR Convergence 2026 insights into rheumatology research, osteoarthritis treatment, personalised medicine in rheumatology and rheumatoid arthritis treatment.

Early Diagnosis and Rheumatoid Arthritis Treatment: Protecting Long-Term Joint Health

Early diagnosis remains an important factor in preventing irreversible damage and preserving physical function in rheumatic diseases. The participant identified two areas where timely intervention could make a particularly meaningful difference: rapidly progressive osteoarthritis and rheumatoid arthritis.

In aggressive forms of osteoarthritis, recognising structural deterioration earlier may help clinicians identify patients at risk of rapid progression. Although disease-modifying options remain limited, earlier assessment can support appropriate management and monitoring.

For rheumatoid arthritis, the benefits of timely intervention are more established.

“In rheumatoid arthritis, early diagnosis and prompt initiation of appropriate treatment remain crucial to achieving sustained remission, preventing joint damage, and preserving long-term functional outcomes.”

ACR Convergence 2026 participant

Rheumatoid arthritis is a chronic inflammatory condition that can cause progressive joint damage when inflammation remains uncontrolled. Early initiation of disease-modifying antirheumatic drugs (DMARDs), followed by regular assessment and treatment adjustment, can help control inflammation and reduce the risk of long-term disability.

However, achieving timely diagnosis is not always straightforward. Symptoms may develop gradually, overlap with other conditions or vary considerably between patients. These challenges reinforce the importance of recognising persistent inflammatory symptoms, obtaining appropriate investigations and ensuring timely access to specialist assessment.

As rheumatoid arthritis treatment continues to evolve, earlier diagnosis and individualised management will remain central to improving long-term outcomes.

Explore ACR Convergence 2026 insights into rheumatology research, osteoarthritis treatment, personalised medicine in rheumatology and rheumatoid arthritis treatment.

Emerging Rheumatology Research: Treatment Safety and Comparative Evidence

Beyond unmet needs and early intervention, the participant highlighted several presentations from ACR Convergence 2026 that could inform future treatment decisions. One area of interest involved predictors of treatment failure with tocilizumab in giant cell arteritis. Understanding which patients are less likely to respond adequately could help clinicians identify those requiring closer monitoring or alternative treatment strategies. Another presentation examined malignancy risk with upadacitinib compared with adalimumab in rheumatoid arthritis.

Treatment safety is particularly important in chronic inflammatory diseases, where patients may require long-term therapy. Comparative safety evidence can help clinicians assess the potential benefits and risks of different treatment options. The participant also highlighted emerging comparisons between IL-17 and IL-23 inhibition in psoriatic arthritis.

Both pathways are relevant to inflammatory disease, but treatment selection may depend on the pattern of joint involvement, associated skin disease and individual patient characteristics. Comparative evidence could help clarify which approaches are most appropriate in different clinical situations.

A further area of interest concerned the risk of demyelinating events with TNF inhibitors compared with conventional synthetic DMARDs in rheumatoid arthritis. Although these events are uncommon, understanding potential neurological risks remains important when evaluating treatment suitability.

Together, these research areas highlight the growing importance of individualised risk-benefit assessment. Treatment decisions increasingly require clinicians to consider not only disease control, but also safety, comorbidities and long-term treatment requirements.

The participant’s comments identified these presentations as clinically relevant areas to follow, rather than establishing that the findings already warrant changes to treatment guidelines.

Emerging Treatment Approaches: What Could Shape Rheumatology Care Next?

Looking beyond the congress, the participant identified several therapeutic developments they are particularly interested in following over the next year. One involves the potential role of medical obesity treatments, particularly glucagon-like peptide-1 (GLP-1)-based therapies, in inflammatory rheumatic diseases.

These treatments are primarily used in metabolic conditions, but researchers are increasingly interested in whether their effects on weight, metabolic health and inflammatory processes could offer additional benefits for patients with rheumatic diseases.

Another area involves monoclonal antibodies targeting interleukin-1 receptor accessory protein (IL-1RAcP), a component involved in inflammatory signalling. Targeting this pathway may offer opportunities to influence inflammatory responses through mechanisms different from those used by established treatments. However, clinical evidence will be needed to establish efficacy, safety and appropriate patient populations.

The participant also expressed interest in combining therapies that act through different biological mechanisms.

“Combination strategies involving targeted therapies, particularly the potential role of combining different therapeutic mechanisms to improve disease control in patients with inadequate responses to existing treatments.”

ACR Convergence 2026 participant

This is particularly relevant for patients who continue to experience active disease despite receiving established therapies. Combining targeted treatments could potentially address multiple inflammatory pathways, but such strategies must be evaluated carefully. Additional immunosuppression, adverse effects and treatment costs are important considerations. These emerging approaches illustrate how rheumatology research is exploring new ways to improve disease control, particularly for patients whose needs remain unmet.

Key Takeaways from ACR Convergence 2026: What Comes Next for Rheumatology?

The participant’s reflections on ACR Convergence 2026 highlight several priorities for future rheumatology research and clinical practice. One of the most significant challenges remains the development of effective disease-modifying osteoarthritis treatments. Regenerative approaches may offer new possibilities, but stronger clinical evidence is needed before their role in routine care can be established.

Personalised medicine is also progressing, with greater attention to biomarkers, disease characteristics and inflammatory pathways. However, more accurate tools are needed to predict individual treatment responses.

Early diagnosis remains essential, particularly in rheumatoid arthritis, where prompt intervention can reduce joint damage and improve long-term functional outcomes.

The congress also brought attention to treatment safety, comparative effectiveness and emerging therapeutic strategies. Research involving GLP-1-based treatments, IL-1RAcP-targeted antibodies and combinations of targeted therapies could provide further insights over the coming years.

Ultimately, progress in rheumatology will depend on translating these developments into treatments that are effective, safe and appropriate for individual patients. As new evidence emerges, the focus will remain on improving disease control, preserving joint function and supporting better long-term quality of life for people living with rheumatic diseases.

What developments in rheumatology research do you believe could have the greatest impact on clinical practice? From emerging treatment approaches to advances in personalised medicine, the future of rheumatology continues to evolve. We would love to hear your perspective on the research priorities and clinical challenges that matter most to you.

Share your thoughts in the comments below.

Join the M3 Panel

Would you like to be rewarded for your medical expertise? Join M3 today and share your opinion

Join the M3 Panel

Would you like to be rewarded for your medical expertise? Join M3 today and share your opinion

You Might Be Interested in:

Are You an Oncologist or Haematologist?

What is your opinion on new technologies and advancements in chemotherapy,  hormone therapy, immunotherapy, and targeted therapy? Join M3 today and share your opinion

Leave a Reply

Your email address will not be published. Required fields are marked *

Join Today

Registration is free and only takes a few clicks

Panel Members

Check your available studies

latest posts